Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma

Trial Profile

A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldesleukin (Primary) ; Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms i i i
  • Most Recent Events

    • 19 Sep 2015 Status changed from planning to completed, as reported by European Clinical Trials Database (EudraCT2010-019033-98)
    • 06 Jul 2015 New trial record
    • 02 Jun 2015 Based on results of a phase I trial (see trial profile 700222282), investigators at the University of Utah are planning to conduct this phase II trial of intratumoural ipilimumab and aldesleukin in conjunction with systemic immunotherapy, according to an abstract presented at ASCO 2015.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top